209 related articles for article (PubMed ID: 31923801)
1. Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance.
Liu Q; Borcherding NC; Shao P; Maina PK; Zhang W; Qi HH
EBioMedicine; 2020 Jan; 51():102612. PubMed ID: 31923801
[TBL] [Abstract][Full Text] [Related]
2. Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Shao P; Liu Q; Maina PK; Cui J; Bair TB; Li T; Umesalma S; Zhang W; Qi HH
Nucleic Acids Res; 2017 Feb; 45(4):1687-1702. PubMed ID: 27899639
[TBL] [Abstract][Full Text] [Related]
3. Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer.
Tseng LL; Cheng HH; Yeh TS; Huang SC; Syu YY; Chuu CP; Yuh CH; Kung HJ; Wang WC
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):24859-24866. PubMed ID: 32958674
[TBL] [Abstract][Full Text] [Related]
4. Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics.
Ma S; Zhang J; Guo Q; Cao C; Bao K; Liu L; Chen CD; Liu Z; Yang J; Yang N; Yao Z; Shi L
Cancer Lett; 2022 Apr; 530():29-44. PubMed ID: 35051531
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
Wang Q; Ma S; Song N; Li X; Liu L; Yang S; Ding X; Shan L; Zhou X; Su D; Wang Y; Zhang Q; Liu X; Yu N; Zhang K; Shang Y; Yao Z; Shi L
J Clin Invest; 2016 Jun; 126(6):2205-20. PubMed ID: 27183383
[TBL] [Abstract][Full Text] [Related]
8. Histone demethylase PHF8 regulates hypoxia signaling through HIF1α and H3K4me3.
Maina PK; Shao P; Jia X; Liu Q; Umesalma S; Marin M; Long D; Concepción-Román S; Qi HH
Biochim Biophys Acta Gene Regul Mech; 2017 Sep; 1860(9):1002-1012. PubMed ID: 28734980
[TBL] [Abstract][Full Text] [Related]
9. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
10. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
12. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.
Lin J; Mao H; Ji Z; Lin W; Wang T
J Cancer Res Ther; 2021 Nov; 17(5):1192-1201. PubMed ID: 34850767
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
15. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.
Mishra A; Hourigan D; Lindsay AJ
Cancer Lett; 2022 Mar; 529():153-167. PubMed ID: 35007696
[TBL] [Abstract][Full Text] [Related]
17. Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study.
Kang SA; Guan JS; Tan HJ; Chu T; Thike AA; Bernadó C; Arribas J; Wong CY; Tan PH; Gudi M; Putti TC; Sohn J; Lim SH; Lee SC; Lim YP
Clin Cancer Res; 2019 Apr; 25(8):2588-2600. PubMed ID: 30593516
[TBL] [Abstract][Full Text] [Related]
18. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
Chung SS; Giehl N; Wu Y; Vadgama JV
Int J Oncol; 2014 Feb; 44(2):403-11. PubMed ID: 24297508
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
20. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]